您的账号已在其他设备登录,您当前账号已强迫下线,
如非您本人操作,建议您在会员中心进行密码修改

确定
收藏 | 浏览44

To evaluate the efficacy and safety of insulin glargine 300U/mL (Gla-300) versus glargine 100U/mL (Gla-100) in adults with type 1 diabetes in Japan over 12months.EDITION JP 1 was a multicentre, randomised, open-label phase 3 study. Following a 6-month on-treatment period, participants continued to receive Gla-300 or Gla-100 once daily, plus mealtime insulin, over a 6-month open-label extension phase. HbA1c, hypoglycaemia, body weight and adverse events were assessed.Overall, 114/122 (93

作者:Munehide, Matsuhisa;Masayoshi, Koyama;Xi, Cheng;Mariko, Sumi;Matthew C, Riddle;Geremia B, Bolli;Takahisa, Hirose

来源:Diabetes research and clinical practice 2016 年 122卷

相似文献
知识库介绍

临床诊疗知识库该平台旨在解决临床医护人员在学习、工作中对医学信息的需求,方便快速、便捷的获取实用的医学信息,辅助临床决策参考。该库包含疾病、药品、检查、指南规范、病例文献及循证文献等多种丰富权威的临床资源。

详细介绍
热门关注
免责声明:本知识库提供的有关内容等信息仅供学习参考,不代替医生的诊断和医嘱。

收藏
| 浏览:44
作者:
Munehide, Matsuhisa;Masayoshi, Koyama;Xi, Cheng;Mariko, Sumi;Matthew C, Riddle;Geremia B, Bolli;Takahisa, Hirose
来源:
Diabetes research and clinical practice 2016 年 122卷
标签:
Glycaemic control Hypoglycaemia Insulin glargine Type 1 diabetes
To evaluate the efficacy and safety of insulin glargine 300U/mL (Gla-300) versus glargine 100U/mL (Gla-100) in adults with type 1 diabetes in Japan over 12months.EDITION JP 1 was a multicentre, randomised, open-label phase 3 study. Following a 6-month on-treatment period, participants continued to receive Gla-300 or Gla-100 once daily, plus mealtime insulin, over a 6-month open-label extension phase. HbA1c, hypoglycaemia, body weight and adverse events were assessed.Overall, 114/122 (93

相似文献